Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H11I3NO4.Na |
Molecular Weight | 672.9553 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].N[C@@H](CC1=CC(I)=C(OC2=CC=C(O)C(I)=C2)C(I)=C1)C([O-])=O
InChI
InChIKey=SBXXSUDPJJJJLC-YDALLXLXSA-M
InChI=1S/C15H12I3NO4.Na/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22;/h1-4,6,12,20H,5,19H2,(H,21,22);/q;+1/p-1/t12-;/m0./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/6617571http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10379s47lbl.pdfCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68014284
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6617571http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10379s47lbl.pdf
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68014284
Liothyronine (CYTOMEL®) is a T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than its prohormone thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3. The mechanisms by which thyroid hormones exert their physiologic action are not well understood. These hormones enhance oxygen consumption by most tissues of the body, increase the basal metabolic rate and the metabolism of carbohydrates, lipids, and proteins. Thus, they exert a profound influence on every organ system in the body and are of particular importance in the development of the central nervous system. Thyroid hormone drugs are indicated: as the replacement or supplemental therapy in patients with hypothyroidism of any etiology; as pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters; as diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1860 |
0.1 nM [Kd] | ||
Target ID: CHEMBL1947 |
0.1 nM [Kd] | ||
Target ID: CHEMBL1860 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12109914 |
0.1 nM [Kd] | ||
Target ID: CHEMBL1947 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12109914 |
0.1 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CYTOMEL Approved UseThyroid hormone drugs are indicated:
1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism.
2. As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s) and multinodular goiter.
3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Launch Date1956 |
|||
Primary | CYTOMEL Approved UseThyroid hormone drugs are indicated:
1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism.
2. As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s) and multinodular goiter.
3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Launch Date1956 |
|||
Diagnostic | CYTOMEL Approved UseThyroid hormone drugs are indicated:
1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism.
2. As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s) and multinodular goiter.
3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Launch Date1956 |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
346 ng/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
342 ng/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
404 ng/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4370 ng × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4740 ng × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4926 ng × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
12929 ng × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
13938 ng × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
22.04 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Disc. AE: Anxiety, Palpitations... AEs leading to discontinuation/dose reduction: Anxiety (severe) Sources: Page: p.2Palpitations Agitation Shortness of breath Irritability Tachycardia Tremor |
15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea Sources: Page: p.2Vomiting Abdominal pain Headache (severe) Confusion Disorientation Diplopia |
50 ug 2 times / day multiple, oral Highest studied dose Dose: 50 ug, 2 times / day Route: oral Route: multiple Dose: 50 ug, 2 times / day Sources: Page: p.3 |
unhealthy, 39 ± 6.2 n = 2 Health Status: unhealthy Condition: Multiple sclerosis Age Group: 39 ± 6.2 Sex: M+F Population Size: 2 Sources: Page: p.3 |
DLT: Anxiety, Tachycardia... Dose limiting toxicities: Anxiety (50%) Sources: Page: p.3Tachycardia (50%) Loose stools (100%) |
37.5 ug 2 times / day multiple, oral MTD Dose: 37.5 ug, 2 times / day Route: oral Route: multiple Dose: 37.5 ug, 2 times / day Sources: Page: p.3 |
unhealthy, 39 ± 6.2 n = 4 Health Status: unhealthy Condition: Multiple sclerosis Age Group: 39 ± 6.2 Sex: M+F Population Size: 4 Sources: Page: p.3 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Agitation | Disc. AE | 10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Irritability | Disc. AE | 10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Palpitations | Disc. AE | 10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Shortness of breath | Disc. AE | 10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Tachycardia | Disc. AE | 10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Tremor | Disc. AE | 10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Anxiety | severe Disc. AE |
10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Abdominal pain | Disc. AE | 15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Confusion | Disc. AE | 15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Diplopia | Disc. AE | 15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Disorientation | Disc. AE | 15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Nausea | Disc. AE | 15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Vomiting | Disc. AE | 15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Headache | severe Disc. AE |
15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Loose stools | 100% DLT |
50 ug 2 times / day multiple, oral Highest studied dose Dose: 50 ug, 2 times / day Route: oral Route: multiple Dose: 50 ug, 2 times / day Sources: Page: p.3 |
unhealthy, 39 ± 6.2 n = 2 Health Status: unhealthy Condition: Multiple sclerosis Age Group: 39 ± 6.2 Sex: M+F Population Size: 2 Sources: Page: p.3 |
Anxiety | 50% DLT |
50 ug 2 times / day multiple, oral Highest studied dose Dose: 50 ug, 2 times / day Route: oral Route: multiple Dose: 50 ug, 2 times / day Sources: Page: p.3 |
unhealthy, 39 ± 6.2 n = 2 Health Status: unhealthy Condition: Multiple sclerosis Age Group: 39 ± 6.2 Sex: M+F Population Size: 2 Sources: Page: p.3 |
Tachycardia | 50% DLT |
50 ug 2 times / day multiple, oral Highest studied dose Dose: 50 ug, 2 times / day Route: oral Route: multiple Dose: 50 ug, 2 times / day Sources: Page: p.3 |
unhealthy, 39 ± 6.2 n = 2 Health Status: unhealthy Condition: Multiple sclerosis Age Group: 39 ± 6.2 Sex: M+F Population Size: 2 Sources: Page: p.3 |
PubMed
Title | Date | PubMed |
---|---|---|
Neurofilament expression in cultured rat adenohypophysial cells. | 2001 |
|
Hypothalamus-hypophysis-thyroid axis, triiodothyronine and antithyroid antibodies in patients with primary and secondary Sjögren's syndrome. | 2001 |
|
Effect of transient early hyperthyroidism on onset of puberty in Suffolk ram lambs. | 2001 Apr |
|
Thyroid hormone increases pacemaker activity in rat neonatal atrial myocytes. | 2001 Apr |
|
The pituitary-thyroid axis in healthy men living under subarctic climatological conditions. | 2001 Apr |
|
Effect of thyroxine administration on the IGF/IGF binding protein system in neonatal and adult thyroidectomized rats. | 2001 Apr |
|
Expression and regulation of osteopontin and connective tissue growth factor transcripts in rat anterior pituitary. | 2001 Apr |
|
Habituation of thermal sensations, skin temperatures, and norepinephrine in men exposed to cold air. | 2001 Apr |
|
Variable effects of goitrogens in inducing precocious metamorphosis in sea lampreys (Petromyzon marinus). | 2001 Apr 15 |
|
Side-effects of iodized oil administration in patients with simple goiter. | 2001 Feb |
|
Changes in serum thyroid hormone levels in newborn calves as a diagnostic index of endemic goiter. | 2001 Feb |
|
[Diabetes mellitus caused by pancreatitis in a bull]. | 2001 Feb |
|
Effects of melatonin in perimenopausal and menopausal women: a randomized and placebo controlled study. | 2001 Feb |
|
Thyroid function after bone marrow transplantation: possible association between immune-mediated thyrotoxicosis and hypothyroidism. | 2001 Feb 15 |
|
Measurement of serum concentrations of free thyroxine, total thyroxine, and total triiodothyronine in cats with hyperthyroidism and cats with nonthyroidal disease. | 2001 Feb 15 |
|
Ramadan fasting alters endocrine and neuroendocrine circadian patterns. Meal-time as a synchronizer in humans? | 2001 Feb 23 |
|
Relationships between plasma levels of organochlorines, retinol and thyroid hormones from polar bears (Ursus maritimus) at Svalbard. | 2001 Feb 23 |
|
What is the optimal treatment for hypothyroidism? | 2001 Feb 5 |
|
Inhibition of T3 production in levothyroxine-treated female mice by the root extract of Convolvulus pluricaulis. | 2001 Jan |
|
Influence of selenium supplements on the post-traumatic alterations of the thyroid axis: a placebo-controlled trial. | 2001 Jan |
|
Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. | 2001 Jan |
|
Direct effect of thyroxine on pig sphincter of Oddi contractility. | 2001 Jan |
|
[Diagnosis of hyperthyroidism]. | 2001 Jan |
|
Impairment in cognitive and exercise performance during prolonged antarctic residence: effect of thyroxine supplementation in the polar triiodothyronine syndrome. | 2001 Jan |
|
Effect of acute elevation of IGF-I on circulating GH, TSH, insulin, IGF-II and IGFBP-3 levels in non-endocrine short stature (NESS). | 2001 Jan |
|
Effect of cold exposure on energy balance and liver respiratory capacity in post-weaning rats fed a high-fat diet. | 2001 Jan |
|
Endogenous depression, thyroid function and acupuncture. | 2001 Jan |
|
Role of thyroid hormones in hepatic effects of peroxisome proliferators. | 2001 Jan-Feb |
|
An array of positioned nucleosomes potentiates thyroid hormone receptor action in vivo. | 2001 Jun 8 |
|
The effects of triiodothyronine augmentation on antithrombin III levels in sepsis. | 2001 Mar |
|
Effects of caloric restriction on skeletal muscle mitochondrial proton leak in aging rats. | 2001 Mar |
|
Characterization of hepatic low-K(m) outer-ring deiodination in red drum (Sciaenops ocellatus). | 2001 Mar |
|
The biological relevance of thyroid hormone receptors in immortalized human umbilical vein endothelial cells. | 2001 Mar |
|
Perioperative considerations in a hypothyroid infant with hepatic haemangioma. | 2001 Mar |
|
Selenium decreases thyroglobulin concentrations but does not affect the increased thyroxine-to-triiodothyronine ratio in children with congenital hypothyroidism. | 2001 Mar |
|
Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study. | 2001 Mar |
|
Usefulness of thyrotropin (TSH)-releasing hormone test and nocturnal surge of TSH for diagnosis of isolated deficit of TSH secretion. | 2001 Mar |
|
Homogeneous enzyme immunoassay for triiodothyronine in serum. | 2001 Mar |
|
Distinct tissue-specific roles for thyroid hormone receptors beta and alpha1 in regulation of type 1 deiodinase expression. | 2001 Mar |
|
Hormone selectivity in thyroid hormone receptors. | 2001 Mar |
|
Thyroid hormones regulate pituitary growth hormone secretagogue receptor gene expression. | 2001 Mar |
|
Regulation of microglial development: a novel role for thyroid hormone. | 2001 Mar 15 |
|
Insulin-like growth factor binding proteins in femoral and vertebral bone marrow stromal cells: expression and regulation by thyroid hormone and dexamethasone. | 2001 Mar 26 |
|
Thyroid hormone promotes serine phosphorylation of p53 by mitogen-activated protein kinase. | 2001 Mar 6 |
|
Regulation of mucous differentiation and mucin gene expression in the tracheobronchial epithelium. | 2001 Mar 7 |
|
Effect of different drugs on the level of DNA-hydrolyzing polyclonal IgG antibodies in sera of patients with Hashimoto's thyroiditis and nontoxic nodal goiter. | 2001 Mar-Apr |
|
Thyroid hormone receptors in neonatal, prepubertal, and adult rat testis. | 2001 Mar-Apr |
|
Circannual pattern of hypothalamic-pituitary-thyroid (HPT) function and mood during extended antarctic residence. | 2001 May |
|
Transcriptional repression by thyroid hormone receptors. A role for receptor homodimers in the recruitment of SMRT corepressor. | 2001 May 18 |
|
Slower skeletal muscle phenotypes are critical for constitutive expression of Hsp70 in overloaded rat plantaris muscle. | 2006 Mar |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1606687
The relative affinity of the rat synaptosomes for various T3 analogs was measured by incubating [3H]T3 with increasing amounts of T3, D-T3, T4, TRIAC and rT3, The results were expressed as the molar ratio of the concentrations of T3 or analog needed to decreaseby 50% the binding of [3H]T3.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1553
Created by
admin on Fri Dec 15 15:08:15 GMT 2023 , Edited by admin on Fri Dec 15 15:08:15 GMT 2023
|
||
|
FDA ORPHAN DRUG |
46090
Created by
admin on Fri Dec 15 15:08:15 GMT 2023 , Edited by admin on Fri Dec 15 15:08:15 GMT 2023
|
||
|
WHO-VATC |
QH03AA02
Created by
admin on Fri Dec 15 15:08:15 GMT 2023 , Edited by admin on Fri Dec 15 15:08:15 GMT 2023
|
||
|
FDA ORPHAN DRUG |
523216
Created by
admin on Fri Dec 15 15:08:15 GMT 2023 , Edited by admin on Fri Dec 15 15:08:15 GMT 2023
|
||
|
WHO-ATC |
H03AA02
Created by
admin on Fri Dec 15 15:08:15 GMT 2023 , Edited by admin on Fri Dec 15 15:08:15 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
GCA9VV7D2N
Created by
admin on Fri Dec 15 15:08:15 GMT 2023 , Edited by admin on Fri Dec 15 15:08:15 GMT 2023
|
PRIMARY | |||
|
80774
Created by
admin on Fri Dec 15 15:08:15 GMT 2023 , Edited by admin on Fri Dec 15 15:08:15 GMT 2023
|
PRIMARY | |||
|
18258
Created by
admin on Fri Dec 15 15:08:15 GMT 2023 , Edited by admin on Fri Dec 15 15:08:15 GMT 2023
|
PRIMARY | |||
|
SUB02931MIG
Created by
admin on Fri Dec 15 15:08:15 GMT 2023 , Edited by admin on Fri Dec 15 15:08:15 GMT 2023
|
PRIMARY | |||
|
GCA9VV7D2N
Created by
admin on Fri Dec 15 15:08:15 GMT 2023 , Edited by admin on Fri Dec 15 15:08:15 GMT 2023
|
PRIMARY | |||
|
100000089973
Created by
admin on Fri Dec 15 15:08:15 GMT 2023 , Edited by admin on Fri Dec 15 15:08:15 GMT 2023
|
PRIMARY | |||
|
m6835
Created by
admin on Fri Dec 15 15:08:15 GMT 2023 , Edited by admin on Fri Dec 15 15:08:15 GMT 2023
|
PRIMARY | Merck Index | ||
|
1368019
Created by
admin on Fri Dec 15 15:08:15 GMT 2023 , Edited by admin on Fri Dec 15 15:08:15 GMT 2023
|
PRIMARY | |||
|
C2581
Created by
admin on Fri Dec 15 15:08:15 GMT 2023 , Edited by admin on Fri Dec 15 15:08:15 GMT 2023
|
PRIMARY | |||
|
CHEMBL1544
Created by
admin on Fri Dec 15 15:08:15 GMT 2023 , Edited by admin on Fri Dec 15 15:08:15 GMT 2023
|
PRIMARY | |||
|
142448
Created by
admin on Fri Dec 15 15:08:15 GMT 2023 , Edited by admin on Fri Dec 15 15:08:15 GMT 2023
|
PRIMARY | RxNorm | ||
|
200-223-5
Created by
admin on Fri Dec 15 15:08:15 GMT 2023 , Edited by admin on Fri Dec 15 15:08:15 GMT 2023
|
PRIMARY | |||
|
DBSALT000321
Created by
admin on Fri Dec 15 15:08:15 GMT 2023 , Edited by admin on Fri Dec 15 15:08:15 GMT 2023
|
PRIMARY | |||
|
DTXSID8047505
Created by
admin on Fri Dec 15 15:08:15 GMT 2023 , Edited by admin on Fri Dec 15 15:08:15 GMT 2023
|
PRIMARY | |||
|
23666110
Created by
admin on Fri Dec 15 15:08:15 GMT 2023 , Edited by admin on Fri Dec 15 15:08:15 GMT 2023
|
PRIMARY | |||
|
758175
Created by
admin on Fri Dec 15 15:08:15 GMT 2023 , Edited by admin on Fri Dec 15 15:08:15 GMT 2023
|
PRIMARY | |||
|
6484
Created by
admin on Fri Dec 15 15:08:15 GMT 2023 , Edited by admin on Fri Dec 15 15:08:15 GMT 2023
|
PRIMARY | |||
|
55-06-1
Created by
admin on Fri Dec 15 15:08:15 GMT 2023 , Edited by admin on Fri Dec 15 15:08:15 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD